Pharmacological
GSK-3 inhibitors are potential drugs for the treatment of
neurodegenerative diseases,
cancer and diabetes. We examined the antiproliferative effects of two
GSK-3 inhibitors,
lithium and
SB-415286, on B65
neuroblastoma cell line. Treatment of B65 cells with either
drug administered separately caused a decrease in cell proliferation that was associated with G(2)/M cell cycle arrest.
Cell-cycle proteins such as
cyclins D, E, A, cdk4 and cdk2 were up-regulated. Since
lithium and SB-415286-induced G(2)/M arrest we studied changes in the expression of
proteins involved in this phase, specifically
cyclin B, cdc2 and the phosphorylated form of this
protein (tyr15-cdc2). Both drugs increased the expression of tyr15-cdc2, thus inhibiting mitosis. On the other hand,
SB-415286 increased the expression of
SIRT2, involved in the regulation of proliferation. Moreover, cell-cycle arrest mediated by
SB-415286 was accompanied by apoptosis that was not prevented by 100 microM of
zVAD-fmk (
benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone), a pan-
caspase inhibitor. Likewise,
GSK-3 inhibitors did not affect the mitochondrial release of
apoptosis inducing factor (AIF). We conclude that inhibitors of
GSK-3 induced cell-cycle arrest, mediated by the phosphorylation of cdc2 and, in the case of
SB-415286,
SIRT2 expression, which induced apoptosis in a
caspase-independent manner.